tumor immunotherapy
Recently Published Documents


TOTAL DOCUMENTS

572
(FIVE YEARS 186)

H-INDEX

52
(FIVE YEARS 13)

Nano Today ◽  
2022 ◽  
Vol 42 ◽  
pp. 101381
Author(s):  
Yanfei Li ◽  
Hongliang Qian ◽  
Xin Huang ◽  
Xiang Zhou ◽  
Bingbing Zhao ◽  
...  

2022 ◽  
Vol 11 ◽  
Author(s):  
Dan Mu ◽  
Pan He ◽  
Yesi Shi ◽  
Lai Jiang ◽  
Gang Liu

Immunotherapy can effectively activate the immune system and reshape the tumor immune microenvironment, which has been an alternative method in cancer therapy besides surgery, radiotherapy, and chemotherapy. However, the current clinical outcomes are not satisfied due to the lack of targeting of the treatment with some unexpected damages to the human body. Recently, cell membrane-based bioinspired nanoparticles for tumor immunotherapy have attracted much attention because of their superior immune regulating, drug delivery, excellent tumor targeting, and biocompatibility. Together, the article reviews the recent progress of cell membrane-based bioinspired nanoparticles for immunotherapy in cancer treatment. We also evaluate the prospect of bioinspired nanoparticles in immunotherapy for cancer. This strategy may open up new research directions for cancer therapy.


2022 ◽  
pp. 231-256
Author(s):  
Jiawei Li ◽  
Elisa Stephens ◽  
Yong Zhang

2022 ◽  
pp. 529-547
Author(s):  
Lanhong Su ◽  
Guiyuan Chen ◽  
Zhaoji Liu ◽  
Yuanzeng Min ◽  
Andrew Z. Wang

2021 ◽  
Vol 23 (2) ◽  
Author(s):  
Changsheng Zhou ◽  
Qianqian Liu ◽  
Yi Xiang ◽  
Xin Gou ◽  
Wengang Li

2021 ◽  
Vol 12 ◽  
Author(s):  
Bingxiang Xu ◽  
Mingjie Lu ◽  
Linlin Yan ◽  
Minghui Ge ◽  
Yong Ren ◽  
...  

Recently, tumor immunotherapy based on immune checkpoint inhibitors (ICI) has been introduced and widely adopted for various tumor types. Nevertheless, tumor immunotherapy has a few drawbacks, including significant uncertainty of outcome, the possibility of severe immune-related adverse events for patients receiving such treatments, and the lack of effective biomarkers to determine the ICI treatments’ responsiveness. DNA methylation profiles were recently identified as an indicator of the tumor immune microenvironment. They serve as a potential hot spot for predicting responses to ICI treatment for their stability and convenience of measurement by liquid biopsy. We demonstrated the possibility of DNA methylation profiles as a predictor for responses to the ICI treatments at the pan-cancer level by analyzing DNA methylation profiles considered responsive and non-responsive to the treatments. An SVM model was built based on this differential analysis in the pan-cancer levels. The performance of the model was then assessed both at the pan-cancer level and in specific tumor types. It was also compared to the existing gene expression profile-based method. DNA methylation profiles were shown to be predictable for the responses to the ICI treatments in the TCGA cases in pan-cancer levels. The proposed SVM model was shown to have high performance in pan-cancer and specific cancer types. This performance was comparable to that of gene expression profile-based one. The combination of the two models had even higher performance, indicating the potential complementarity of the DNA methylation and gene expression profiles in the prediction of ICI treatment responses.


2021 ◽  
Vol 33 (12) ◽  
pp. 2305-2306
Author(s):  
Ameeta Kelekar ◽  
Stephen C. Jameson

Biomaterials ◽  
2021 ◽  
pp. 121341
Author(s):  
Yingmei Luo ◽  
Ze Chen ◽  
Mingjian Sun ◽  
Baohong Li ◽  
Fan Pan ◽  
...  
Keyword(s):  
T Cell ◽  

Sign in / Sign up

Export Citation Format

Share Document